Welgene Biotech Co.,Ltd.

Taipei Exchange 6661.TWO

Welgene Biotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2023: 42.67%

Welgene Biotech Co.,Ltd. Gross Profit Margin is 42.67% for the year ending December 31, 2023, a -3.13% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Welgene Biotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2022 was 44.05%, a 3.35% change year over year.
Welgene Biotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2021 was 42.62%, a 4.55% change year over year.
Welgene Biotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2020 was 40.77%, a -2.49% change year over year.
Welgene Biotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2019 was 41.81%, a -9.79% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Taipei Exchange: 6661.TWO

Welgene Biotech Co.,Ltd.

CEO	Dr. Yi Xing Lin
IPO Date	Oct. 23, 2017
Location	Taiwan
Headquarters	No. 3, Yuanyuan Street
Employees	80
Sector	Health Care
Industries Biotechnology Research & Consulting

Description

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.

Key trends

Past 5 years